CSL Financial Results Distorted By Currency Effects

BMI View: Australian firm CSL needs to aggressively increase its exposure in emerging markets. The manufacturer of plasma therapeutics has a specialist product portfolio that meets medical needs. However, CSL is increasingly facing operational headwinds - such as healthcare reforms, austerity measures and rigorous competition - in developed states.

To read the full article, please choose one of the following options: